Kiniksa Pharmaceuticals International (KNSA) Projected to Announce Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is projected to post its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect Kiniksa Pharmaceuticals International to post earnings of $0.30 per share and revenue of $226.4880 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. During the same period in the prior year, the company earned $0.11 EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year.

On average, analysts expect Kiniksa Pharmaceuticals International to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Shares of KNSA opened at $62.84 on Friday. The company’s fifty day moving average is $56.87 and its 200 day moving average is $49.97. Kiniksa Pharmaceuticals International has a fifty-two week low of $26.27 and a fifty-two week high of $67.53. The stock has a market capitalization of $4.83 billion, a PE ratio of 69.82 and a beta of 0.07.

In related news, Director Barry D. Quart sold 13,099 shares of the firm’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total value of $656,259.90. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at $628,554.60. This trade represents a 51.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Also, insider John F. Paolini sold 58,424 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the transaction, the insider owned 65,623 shares in the company, valued at $3,524,611.33. This trade represents a 47.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Insiders sold a total of 628,427 shares of company stock worth $32,833,228 over the last three months. 51.98% of the stock is owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals International by 2.3% in the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after purchasing an additional 90,194 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Kiniksa Pharmaceuticals International by 45.3% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after acquiring an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd grew its position in Ki...